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Chronic kidney disease (CKD) has been associated with worse in-hospital and long-term outcomes after per-cutaneous coronary intervention (PCI).1-7 However, 
little information exists regarding the effect of CKD on the 
outcomes of chronic total occlusion (CTO)-PCI.7 Patients 
with CKD often have multiple comorbidities and increased 
coronary lesion complexity that could adversely affect PCI 
outcomes. Accordingly, we examined a contemporary mul-
ticenter CTO-PCI registry to examine the impact of CKD 
on the safety and efficacy of CTO-PCI.
Methods
We examined the clinical, angiographic, and procedural 
characteristics of 1979 patients who underwent 2040 CTO-
PCIs and were enrolled in the PROGRESS CTO (Prospec-
tive Global Registry for the Study of Chronic Total Occlusion 
Intervention; NCT02061436) registry between May 2012 
and November 2017 at 18 centers in the United States, Eu-
rope, and Russia (Appendix 1). The study was approved by 
the institutional review board of each site. Some centers only 
enrolled patients during part of the study period due to par-
ticipation in other studies. 
Renal function assessment. The estimated glomerular 
filtration rate (eGFR) was calculated using the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI) formula 
and the serum creatinine measurement obtained prior to and 
temporally closest to the index procedure.8 Patient classifica-
tion was based upon the Kidney Disease: Improving Global 
Outcomes (KDOKI)9 and National Kidney Foundation Kid-
ney Disease Outcomes Quality Initiative (NKF-KDOQI)10 
guidelines: normal or high (G1), ≥90 mL/min/1.73 m2; mild-
ly decreased (G2), 60-89 mL/min/1.73 m2; mildly to mod-
erately decreased (G3a), 45-59 mL/min/1.73 m2; moderately 
to severely decreased (G3b), 30-44 mL/min/1.73 m2; severe-
ly decreased (G4), <29 mL/min/1.73 m2; or kidney failure 
(G5), <29 mL/min/1.73 m2. CKD was defined as eGFR <60 
mL/min/1.73 m2 (composite of the G3a, G3b, G4, and G5 
groups); eGFR ≥60 mL/min/1.73 m2 (composite of the G1 
In-Hospital Outcomes of Chronic Total Occlusion 
Percutaneous Coronary Intervention in Patients With 
Chronic Kidney Disease 
Peter Tajti, MD1,2;  Aris Karatasakis, MD3;  Barbara A. Danek, MD3;  Khaldoon Alaswad, MD4;  
Dimitri Karmpaliotis, MD, PhD5;  Farouc A. Jaffer, MD, PhD6;  James W. Choi, MD7;  Robert W. Yeh, MD, MSc8;  
Mitul Patel, MD9;  Ehtisham Mahmud, MD9;  M. Nicholas Burke, MD1;  Oleg Krestyaninov, MD10; 
Dmitrii Khelimskii, MD10;  Catalin Toma, MD11;  Anthony H. Doing, MD12;  Barry Uretsky, MD13;  
Michalis Koutouzis, MD14;  Ioannis Tsiafoutis, MD14;  R. Michael Wyman, MD15;  Santiago Garcia, MD16;  
Elizabeth Holper, MD17;  Iosif Xenogiannis, MD1;  Bavana V. Rangan, BDS, MPH3;  Subhash Banerjee, MD3; 
Imre Ungi, MD, PhD2;  Emmanouil S. Brilakis, MD, PhD1
ABSTRACT: Objectives. The effect of chronic kidney disease (CKD) on in-hospital outcomes of chronic total occlusion (CTO) percu-
taneous coronary intervention (PCI) has received limited study. Methods. We evaluated the prevalence of CKD and its impact on 
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confidence interval, 0.8-2.7; P=.28). Conclusions. CKD is common among patients undergoing CTO-PCI. High success rates can be 
achieved in patients with decreased glomerular filtration rate, but CKD may be associated with higher in-hospital mortality. 
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and G2 groups) was considered normal. 
Patients undergoing dialysis were classi-
fied in the lowest eGFR group for all 
analyses. All patients had at least one cre-
atinine measurement performed within 
6 months prior to the index procedure. 
Definitions. Coronary CTOs were 
defined as coronary lesions with 
Thrombolysis in Myocardial Infarc-
tion (TIMI) grade flow 0 of at least 
3-month duration. Estimation of the oc-
clusion duration was based on first onset 
of anginal symptoms, prior history of 
myocardial infarction in the target-ves-
sel territory, or comparison with a 
prior angiogram. Calcification was as-
sessed by angiography as mild (spots), 
moderate (involving ≤50% of the ref-
erence lesion diameter), or severe (in-
volving >50% of the reference lesion 
diameter). Moderate proximal vessel tor-
tuosity was defined as the presence of 
at least 2 bends >70° or 1 bend >90° 
and severe tortuosity as 2 bends >90° 
or 1 bend >120° in the CTO vessel. 
Interventional collaterals were defined as 
collaterals deemed amenable to cross-
ing by a guidewire and a microcath-
eter by the operator. The J-CTO score 
was calculated as described by Mori-
no et al,11 the PROGRESS CTO score 
as described by Christopoulos et al,12 
and the PROGRESS CTO Complica-
tion score as described by Danek et al.13 
Technical success of CTO-PCI was de-
fined as successful CTO revasculariza-
tion with achievement of <30% resid-
ual diameter stenosis within the treated 
segment and restoration of TIMI grade 
3 antegrade flow. Procedural success was 
defined as achievement of technical 
success with no in-hospital major ad-
verse cardiac event (MACE). In-hospital 
MACE included any of the following 
adverse events prior to hospital dis-
charge: death, myocardial infarction 
(MI), recurrent symptoms requiring 
urgent repeat target-vessel revascular-
ization with PCI or coronary artery 
bypass graft (CABG) surgery, tampon-
ade requiring either pericardiocentesis 
or surgery, and stroke. Periprocedural and 
late in-hospital MI were defined accord-
ing to the Third Universal Definition 
Table 1. Clinical characteristics of the study patients, classified according to 
preprocedural estimated glomerular filtration rate.








Age (years) 65.0 ± 10.0 70.2 ± 8.6 63.1 ± 8.6 <.001
Male gender 86% 82% 87% <.01
Black race 7% 8% 6% .17
BMI (kg/m2) 30.5 ± 6.1 30.7 ± 6.4 30.5 ± 6.0 .45
Baseline creatinine (mg/dL) 1.2 ± 0.9 1.8 ± 1.5 1.0 ± 0.2 <.001
eGFR CKD-EPI formula 
(mL/min/1.73 m2)
72.8 ± 21.9 45.1 ± 13.6 83.0 ± 14.2 <.001
Dialysis 2% 8% 0% <.001
Current smoker 23% 16% 26% <.001
Diabetes 44% 56% 39% <.001
Dyslipidemia 92% 92% 93% .68
Hypertension 90% 94% 88% <.001
Prior MI 49% 47% 56% <.01
Heart failure 31% 42% 27% <.001
Prior PCI 60% 63% 58% .05
Prior CABG 32% 40% 29% <.001
Prior CVD 13% 15% 11% .02
PAD 15% 22% 13% <.001
Ad hoc CTO-PCI 14% 13% 14% .61
Chronic lung disease 14% 14% 17% .14
Left ventricular EF (%) 50.3 ± 13.4 47.8 ± 13.8 51.2 ± 13.1 <.001
CAD presentation <.001
   ACS 26% 32% 24%
   Stable angina 65% 58% 67%
   Other 10% 11% 9%
CCS angina classification .52
   Class ≤1 10% 11% 10%
   Class ≥2 90% 89% 90%
Antianginal medication used
   Long-acting nitrates 39% 42% 38% .06
   Beta-blockers 84% 85% 83% .41
   Calcium-channel blockers 24% 28% 23% .03
   Ranolazine 14% 17% 14% .09
Data provided as percentage or mean ± standard deviation.
ACS = acute coronary syndrome; BMI = body mass index; CABG = coronary artery bypass graft; 
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; CAD = coronary artery disease; 
CTO = chronic total occlusion; CVD = cerebrovascular disease; EF = ejection fraction; eGFR = es-
timated glomerular filtration rate; PCI = percutaneous coronary intervention; PAD = peripheral 




















Vol. 30, No. 11, NoVember 2018 E115
CTO-PCI In PaTIenTs WITh CKD TaJTI, eT al.
of Myocardial Infarction.14 Bleeding was defined according 
to the National Cardiovascular Data Registry CathPCI da-
tabase, and included suspected/confirmed bleeding occur-
ring within 72 hours of the procedure and associated with 
any of the following: (1) hemoglobin drop of ≥3 g/dL; (2) 
transfusion with whole blood or packed red blood cells; 
or (3) procedural intervention/surgery at bleeding site to 
reverse or correct the bleed. Procedure time was calculated 
from administration of local anesthetic for vascular access 
to removal of the last catheter. 
Statistical analysis. Categorical variables were de-
scribed using percentages and compared between groups 
using Pearson’s Chi-squared test or the Cochran-Armit-
age test for trend. Continuous variables were described as 
mean ± standard deviation or median (interquartile range 
[IQR]) and compared using the Student’s t-test or Wil-
coxon rank-sum test. Multivariable logistic regression was 
used to examine the association between eGFR/dialysis and 
MACE after adjusting for confounding variables selected on 
the grounds of (1) univariable associ-
ation in the present study (P<.10); or 
(2) previously established links with 
MACE. Such variables included age, 
gender, body mass index, diabetes mel-
litus, hypertension, peripheral arterial 
disease, chronic lung disease, histo-
ry of heart failure, MI, stroke, PCI or 
CABG, occlusion length, degree of 
lesion calcification, proximal cap mor-
phology, and utilization of a retrograde 
approach. The group with the highest 
eGFR (≥90 mL/min/1.73 m2) was 
used as reference category for renal 
function. Stepwise backward elimina-
tion was used to form the final model. 
A two-sided P-value of <.05 was con-
sidered statistically significant. All sta-
tistical analyses were performed with 
JMP 13.0 (SAS Institute).
Results
The prevalence of CKD was 27% 
(535 of 1979 patients). Patients with 
CKD were more likely to be older and 
female, and to have hypertension, dia-
betes mellitus, heart failure, peripheral 
arterial disease, prior MI, PCI, CABG 
and stroke, and had lower left ventric-
ular ejection fraction, but were less 
likely to be active smokers (Table 1). 
The most common CTO target vessel 
was  the right coronary artery (54%), 
followed by the left anterior descend-
ing (24%) and the circumflex (21%) 
arteries. CKD patients were more likely to have lesions with 
moderate or severe calcification, proximal vessel tortuosity, 
and diseased distal target vessel. They also had more complex 
lesions with higher J-CTO scores (2.6 ± 1.3 vs 2.4 ± 1.3; 
P=.01) and PROGRESS CTO scores (1.4 ± 1.1 vs 1.3 ± 
1.0; P=.03) (Table 2).
Overall technical and procedural rates were 85% and 
84%, respectively, and were similar in patients with and 
without CKD (Figure 1). Crossing strategies (Table 3) were 
similar for patients with and without CKD; however, ret-
rograde techniques were used more frequently as the initial 
crossing approach in the CKD group (17% vs 13%; P=.04). 
Left ventricular assist devices were used more commonly 
in CKD patients (8% vs 4%; P<.001), for either prophylac-
tic cardiac support (5% vs 3%; P<.01) or emergency car-
diac support (2% vs 1%; P<.01). Procedures performed in 
CKD patients had longer procedural times (134 min [IQR, 
85-200 min] vs 119 min [IQR, 77-185 min]; P<.01) and 
fluoroscopy times (48.9 min [IQR, 27.3-79.2 min] vs 41.4 
Table 2. Angiographic characteristics of the study lesions, classified according to 
preprocedural estimated glomerular filtration rate.









   RCA 54% 53% 55%
   LAD 24% 24% 24%
   LCX 21% 23% 20%
   Other 1% 1% 1%
CTO length (mm) 32.7 ± 23.3 33.4 ± 23.3 32.4 ± 23.4 .41
Vessel diameter (mm) 2.8 ± 0.5 2.8 ± 0.5 2.8 ± 0.5 .88
Proximal cap ambiguity 33% 34% 33% .58
Blunt/no stump 53% 51% 53% .42
Bifurcation at distal cap 33% 35% 32% .37
Diseased distal landing zone 32% 36% 30% .02
Interventional collaterals 57% 56% 57% .48
Moderate/severe calcification 49% 59% 46% <.001
Moderate/severe tortuosity 33% 37% 32% .02
In-stent restenosis 16% 16% 16% .89
Previously failed CTO-PCI 20% 20% 20% .65
J-CTO score 2.5 ± 1.3 2.6 ± 1.3 2.4 ± 1.3 .01
PROGRESS CTO score 1.3 ± 1.0 1.4 ± 1.1 1.3 ± 1.0 .03
PROGRESS CTO 
complication score
3.0 ± 2.0 3.7 ± 1.8 2.8 ± 2.0 <.001
Data provided as percentage or mean ± standard deviation.
CTO = chronic total occlusion; J = Japan; eGFR = estimated glomerular filtration rate; LAD = left 
anterior descending artery; LCX = left circumflex artery; PCI = percutaneous coronary interven-
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min [IQR, 25.3-70.3 min]; 
P<.01), similar air kerma 
patient radiation dose (3.2 
Gray [IQR, 2.0-5.2 Gray] 
vs 3.0 Gray [1.8-4.7 Gray]; 
P=.14), and lower contrast 
volume (250 mL [IQR, 180-
340 mL] vs 260 mL [IQR, 
200-350 mL]; P<.02).
The overall in-hospital 
MACE rate was 2.7% (54 
patients) (Table 4) and was 
higher among CKD pa-
tients (4.3% vs 2.2%; P<.01) 
(Figure 1), driven by higher 
in-hospital mortality (1.9% 
vs 0.3%; P<.001). We ob-
served an inverse graded 
dose-response relationship 
between MACE and eGFR 
(P for trend =.03) (Figure 
2); this was largely due to 
an increase in in-hospital 
mortality with worsening 
eGFR. Four patients died 
in the non-CKD group due 
to coronary perforation (1 
hemothorax, 1 intramural 
cardiac hematoma, 2 coro-
nary tamponade with sub-
sequent cardiogenic shock), 
and 10 patients died in the 
CKD group (4 patients 
suffered cardiogenic shock 
after coronary perforation; 
1 patient suffered cardiac 
arrest after new MI; 1 pa-
tient died from multiple or-
gan dysfunction; 2 patients 
died from progressive car-
diogenic shock despite use 
of a left ventricular assist 
device; 1 patient died from 
hemorrhagic stroke; and 1 
patient died from hemor-
rhagic shock secondary to 
a vascular access compli-
cation). After adjustment 
for potential confounders, 
no independent association 
was found between renal 
function/dialysis status and 
overall MACE rate (Table 
5); however, the association 
Table 3. Procedural characteristics classified according to preprocedural estimated glomerular 
filtration rate.







Dual injection 70% 71% 70% .70
Crossing strategies utilized
   AWE 82% 79% 83% .07
   Retrograde 35% 35% 34% .59
   ADR 32% 32% 32% .98
First crossing strategy .04
   AWE 77% 74% 79%
   Retrograde 14% 17% 13%




   AWE 46% 45% 46%
   Retrograde 21% 20% 21%
   ADR 19% 21% 18%
   None 15% 14% 15%
Access site
   Right femoral 78% 80% 77% .26
   Left femoral 50% 53% 48% .05
   Right radial 33% 30% 34% .08
   Left radial 18% 19% 17% .22
Number of stentsa 2.4 ± 1.2 2.5 ± 1.3 2.4 ± 1.1 .06
Non-CTO PCI 28% 29% 28% .58
Procedure time (min) 123 (80-190) 134 (85-200) 119 (77-185) <.01
Contrast volume (mL) 255 (190-350) 250 (180-340) 260 (200-350) .02
Fluoroscopy time (min) 43.4 (25.8-72.5) 48.9 (27.3-79.2) 41.4 (25.3-70.3) <.01
Patient AK dose (Gray) 3.1 (1.9-4.8) 3.2 (2.0-5.2) 3.0 (1.8-4.7) .14
LVAD used 5% 8% 4% <.001
   Urgent 1% 2% 1% <.01
   Prophylactic 3% 5% 3% <.01
LVAD type
   Intraaortic balloon pump 1% 1% 1% .82
   Impella 2.5b 1% 2% 1% .046
   Impella 5.0b 0% 0% 0% —
   Impella CPb 2% 3% 1% <.001
   Tandem Heartc 1% 2% 1% <.01
Length of in-hospital stay 
(days)
1 (1-2) 1 (1-2) 1 (1-2) .35
Data provided as percentage, mean ± standard deviation, or median (interquartile range).
aFor procedures with technical success only; bManufactured by Abiomed; cManufactured by TandemLife.
AWE = antegrade wire escalation; ADR = antegrade dissection and re-entry; AK = air kerma; CTO = chronic 
total occlusion; eGFR = estimated glomerular filtration rate; LVAD = left ventricular assist device; PCI = per-
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between CKD and in-hospital mortality persisted after ad-
justment (odds ratio [OR], 4.4; 95% confidence interval 
[CI], 1.2-16.0; P=.02). Bleeding was observed in 22 patients 
(1.1%), as follows: access site in 14 patients, gastrointestinal 
in 2 patients, retroperitoneal in 4 patients, genito-urinary in 
1 patient, and hemothorax in 1 patient. Bleeding was more 
frequent among patients with 
CKD (2.2% vs 0.7%; P<.01). 
Contrast-induced nephrop-
athy (CIN) was diagnosed in 
4 patients (0.4%) during the 
hospital stay, requiring new 
dialysis in 1 patient. Acute 
kidney injury only occurred 
in patients with decreased kid-
ney function (1.6% vs 0.0%; 
P<.01).
Forty-five patients (2%) 
were undergoing dialysis at 
the time the procedure was 
performed. Compared with 
non-dialysis patients, those 
undergoing dialysis had nu-
merically lower technical suc-
cess (80% vs 85%; P=.31) and 
procedural success (78% vs 
84%; P=.28) and numerically 
higher incidence of in-hos-
pital MACE (6.7% vs 2.7%; 
P=.10). 
Discussion
Our study provides novel in-
sights into the acute outcomes 
of CKD patients undergoing 
CTO-PCI, as follows: (1) CKD 
was common in the CTO-PCI 
population, with approximately 
one-third of patients having an 
eGFR of <60 mL/min/1.73 
m2; (2) CKD patients, even 
those with severely reduced re-
nal function (eGFR<30 mL/
min/1.73 m2) had similarly high 
technical success rates vs non-
CKD patients; and (3) CKD 
patients had higher in-hospital 
mortality rates. 
Several pathophysiological 
links have been established be-
tween renal dysfunction and 
progression of coronary artery 
disease, including a pro-in-
flammatory and hypercoagu-
lable state,15 homocysteinemia,16 arterial calcification,17 and 
endothelial dysfunction.18,19 CKD is consistently associated 
with worse in-hospital3,6,20 and long-term outcomes1,5,21,22 af-
ter PCI, but to date, limited information has been published 
regarding procedural and in-hospital outcomes of patients 
with CKD undergoing CTO-PCI. 
Table 4. Procedural and in-hospital complications, classified according to preprocedural 
estimated glomerular filtration rate.







Major adverse cardiovascular events 2.7% 4.3% 2.2% .01
   Death 0.7% 1.9% 0.3% <.001
   Acute myocardial infarction 1.0% 1.1% 0.9% .65
   Stroke 0.3% 0.6% 0.2% .20
   Emergency re-PCI 0.2% 0.0% 0.3% .22
   Emergency surgery 0.2% 0.2% 0.1% .81
   Pericardiocentesis 1.0% 1.5% 0.8% .14
Contrast induced nephropathya 0.4% 1.6% 0.0% <.01
Perforation 3.3% 3.7% 3.2% .54
Bleeding 1.1% 2.2% 0.7% <.01
Data presented as percentages. aProspective data collection started in 2016. 
PCI = percutaneous coronary intervention; GFR = estimated glomerular filtration rate.
Table 5. Crude and adjusted odds ratios for in-hospital major adverse cardiovascular 










CKD vs no CKD
   ≥60 mL/min/1.73 m2 1.0 (Ref) — 1.0 (Ref) —
   <60 mL/min/1.73 m2 2.1 (1.2-3.5) .01 1.4 (0.8, 2.7) .28
According to eGFR stage
   ≥90 mL/min/1.73 m2 1.0 (Ref) — 1.0 (Ref) —
   60-90 mL/min/1.73 m2 2.1 (0.8-5.1) .11 1.1 (0.4-2.8) .92
   30-60 mL/min/1.73 m2 3.2 (1.3-8.2) .01 1.4 (0.5-4.2) .54
   <30 mL/min/1.73 m2 5.4 (1.6-18.3) <.01 2.1 (0.5-8.6) .30
According to dialysis status
   Non-dialyzed 1.0 (Ref) — 1.0 (Ref) -
   Dialyzed 2.6 (0.8-8.7) .12 3.1 (0.8-11.3) .10
According to CV/eGFR ratioa
   ≥60 ml/min/1.73m2 1.15 (0.97-1.37) .13 0.97 (0.76-1.24) .79
   <60 ml/min/1.73m2 1.02 (1.00-1.04) .10 1.02 (1.00-1.04) .07
aPer 1 unit change.
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In our study, 27% of patients undergoing CTO-PCI had 
an eGFR of <60 mL/min/1.73 m2, a finding consistent with 
previous reports.7,23,24 Declining renal function did not sig-
nificantly affect the technical success of CTO-PCI despite 
being associated with several comorbidities, such as prior MI 
and prior CABG, which have been associated with technical 
failure in other studies.25 Moreover, patients with CKD were 
more likely to have moderate or severe calcification and 
proximal tortuosity that could also hinder coronary revascu-
larization.12,25 Although overall in-hospital MACE increased 
significantly and incrementally with decreasing renal func-
tion, this association was no longer present on multivariable 
analysis. However, in-hospital mortality was significantly 
higher in patients with CKD, an association that persisted 
after multivariable adjustment. This finding, which is in line 
with previous reports of outcomes after non-CTO PCI and 
CTO-PCI in patients with CKD, should be incorporated in 
the decision-making process for patients with a CTO and 
CKD. Current prediction models for technical success and 
adverse events of CTO-PCI, such as the PROGRESS CTO 
score12 and PROGRESS CTO Complications score,13 do 
not include CKD.
In a single-center study, Stahli et al examined long-term 
outcomes after CTO-PCI among 2002 patients stratified by 
the patients’ baseline eGFR.7 During a median follow-up 
of 2.6 years, higher eGFR was associated with lower all-
cause mortality (hazard ratio [HR], 0.98; 95% CI, 0.98-0.99; 
P<.001). However, patients with failed CTO-PCI had worse 
long-term survival, regardless of whether they had CKD 
(eGFR <60 mL/min/1.73 m2; HR, 1.59; 95% CI, 1.08-
2.32; P=.02) or preserved renal function (eGFR >60 mL/
min/1.73 m2; HR, 1.73; 95% CI, 1.15-2.60; P<.01). Stahli 
et al reported significantly different procedural success rates 
for CTO-PCI in patients with different stages of renal dys-
function (range, 69%-86%; P for trend <.001); however, in 
our study, the procedural outcomes were similar in patients 
with various degrees of renal dysfunction (range, 78%-85%; 
P for trend =.69). 
Dialysis patients are known to have worse in-hospital 
and long-term outcomes after PCI,3 as was also observed 
in our study. This is likely related to higher angiographic 
complexity (especially more severe calcification) and more 
comorbidities that may predispose to complications (such 
as bleeding) or decrease the tolerance of a complication. If 
feasible, CABG might provide good long-term outcomes in 
dialysis patients.26-28
Prior publications of CTO-PCI in CKD patients fo-
cused mostly on the incidence of CIN (6.2%-9.4%) (Ta-
ble 6).23,24,29-33 Liu et al compared patients with renal failure 
(defined as creatinine clearance of <90 mL/min/1.73 m2) 
who did (n = 359) or did not undergo CTO-PCI (n = 142), 
and reported that high technical success (89%) and improved 
long-term outcomes could be achieved in the former group, 
without increasing the risk for CIN (adjusted OR, 0.88; 
95% CI, 0.41-1.93).24 Liu et al developed a risk-stratification 
model for predicting CIN from a cohort of 728 patients: 
age ≥75 years, left ventricular ejection fraction <40%, and 
baseline serum creatinine >1.5 mg/dL were identified as in-
dependent predictors for CIN.33 Bataille et al investigated 
the interaction between CKD and CTO in a non-infarct re-
lated artery on short-term (30-day) and long-term (1-year) 
outcomes after PCI for ST-segment elevation acute MI,31 
and found that the prevalence of CTOs was twice as high 
in CKD patients as compared with patients who did not 
have CKD. Lee et al evaluated the effect of CTO-PCI with 
periprocedural MI on long-term outcomes of 1058 patients 
who underwent successful CTO revascularization.34 During 
a median follow-up of 4.4 years, CKD was independently 
associated with higher all-cause mortality (HR, 3.39; 95% 
CI, 1.48-7.75; P<.01). 
Study limitations. First, this was a retrospective, obser-
vational study, and is subject to all the limitations of such 
FIGURE 1. Technical success, procedural success, and in-hospital 
major adverse cardiovascular event (MACE) rates in patients 
with and without chronic kidney disease (CKD).
FIGURE 2. Technical success, procedural success, and in-hos-
pital major adverse cardiovascular event (MACE) rates in the 
study patients, classified according to preprocedural estimated 
glomerular filtration rate (eGFR).
                               P for trend
Technical success          .77
Procedural success        .69
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studies. Second, eGFR calculations were made using only 
a single creatinine measurement performed closest to the 
procedure that was recorded as part of the study; data on 
urine albumin, or specific functional and structural indica-
tors for CKD, were not collected. Given these limitations, 
CKD classification in our group could be subject to selec-
tion bias; however, the prevalence of CKD in our study is in 
line with prior studies. Third, there was no core laboratory 
adjudication of angiograms and no clinical event adjudica-
tion. Fourth, limited data were available on the incidence of 
Table 6. Studies examining the effect of chronic kidney disease (CKD) on chronic total occlusion (CTO) percutaneous coronary 
intervention (PCI).
Author Year Prevalence of CKDa 








Aguiar-Souto et al30 2008 65 (28%) n/a n/a CINa incidence: 6.2%. Contrast vol-
ume, eGFR, and Mehran risk score 
were not predictive of CIN.
Bataille et al31 2013 45 (29%) n/a n/a Compared to patients with normal 
renal function, patients with CKD 
undergoing primary PCI for STEMI 
were twice as likely to have a CTO in 
a non-infarct related artery (13.4% vs 
7.1%; P<.001).
Lin et al32 2014 206 (40%) n/a n/a CIN incidence: 5.4%. Age >75 years, 
Mehran risk score, and severe prox-
imal tortuosity were independent 
predictors of CIN after CTO-PCI.
Liu et al29 2015 85 (100%c) 85% Death: 0.0%
Stroke: 0.0%
CIN incidence was similar in patients 
without CTO, patients with CTO 
target lesion, and patients with CTO 
as non-target lesion (11.4% vs 9.4% 
vs 6.7%, respectively; P=.34). Age 
≥75 years was the only independent 
predictor of CIN.
Liu et al24 2016 359/154b (100%c) 89% MI: 0.0% 
Stroke: 0.3% 
Death: 0.6%
In patients with CTO and chronic 
kidney disease undergoing angiog-
raphy, attempted CTO recanaliza-
tion was associated with reduced 
long-term mortality (adjusted hazard 
ratio: 0.38; 95% confidence interval, 
0.18-0.83; P=.02), without increase in 
CIN incidence (8.6% vs 10%; P=.13).




Decreasing baseline renal function 
was associated with higher all-
cause mortality. CTO-PCI failure was 
associated with higher long-term 
mortality regardless of baseline renal 
function.
Zhang et al23 2016 86 (18%) 100%c n/a Patients with CTO benefit from 
revascularization regardless of CKD 
status (longer overall and MACE-free 
survival), but CKD attenuated this 
benefit.




High success rate of CTO-PCI can be 
achieved in patients with and with-
out CKD, but CKD may be associated 
with increased in-hospital mortality 
but not MACE.
aDefinition varies according to study.
b359 patients had a creatinine clearance (CrCl) <90 mL/min and 154 patients had CrCl <60 mL/min.
cVariable examined was an inclusion criterion in these studies.
CIN = contrast-induced nephropathy; eGFR = estimated glomerular filtration rate; MACE = major adverse cardiovascular event; MI = myocardial 
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CIN and new need for in-hospital dialysis due to the short-
er data collection period. Fifth, no data were available on 
preprocedural hydration, other interventional or diagnostic 
procedures that were performed prior to PCI, or the type of 
contrast agent utilized. 
Conclusion
CKD is common among patients undergoing CTO-PCI. 
High procedural success rates can be achieved in CKD pa-
tients, but they may have increased risk for in-hospital death. 
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